At the news
? NEUTRALIMPACT 5/10 424B5 filed Apr 8, 2026 at 16:13 ET
Phio Pharmaceuticals is conducting an at-the-market offering of up to $6.36 million in common stock through H.C. Wainwright & Co., with proceeds intended for advancing PH-762 into a Phase 2b/3 trial and general working capital. The offering follows a prior shelf registration and introduces potential near-term dilution.
- Company is offering up to $6,360,000 in common stock through an at-the-market (ATM) offering with H.C. Wainwright & Co.
- Proceeds will fund development of PH-762 in an expected Phase 2b/3 clinical trial for cutaneous squamous cell carcinoma, other development activities, and general working capital needs.
- The offering is subject to a 3.0% commission paid to the sales agent.
- As of December 31, 2025, there were 11,617,250 shares outstanding, with up to 16,586,000 shares to be outstanding after the offering.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access